文献速递心脑血管急症

血流储备分数指导的完全血运重建与仅罪犯血管血运重建在非ST段抬高型心肌梗死合并多支血管病变中的比较:SLIM随机临床试验

Fractional Flow Reserve-Guided Complete vs Culprit-Only Revascularization in Non-ST-Elevation Myocardial Infarction and Multivessel Disease: The SLIM Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01
一句话结论NSTEMI合并多支血管病变患者,在成功处理罪犯血管后,FFR指导的完全血运重建较仅罪犯血管血运重建显著降低1年主要复合终点(5.5% vs 13.6%,HR 0.38),主要由再次血运重建减少驱动。

SLIM研究为前瞻性、研究者发起、多中心、国际随机临床试验,在欧洲9家医院纳入478例NSTEMI合并多支血管病变且罪犯血管已成功血运重建的患者,随机分为FFR指导的完全血运重建组(240例)与仅罪犯血管血运重建组(238例,允许6周内分期血运重建)。主要终点为1年全因死亡、非致死性心肌梗死、任何血运重建和卒中的复合终点,完全血运重建组13例(5.5%)vs 仅罪犯血管组32例(13.6%)(HR 0.38,95%CI 0.20-0.72,P=0.003)。任何血运重建(3.0% vs 11.5%,HR 0.24,95%CI 0.11-0.56,P<0.001)和净不良临床事件(6.3% vs 15.3%,HR 0.39,95%CI 0.21-0.70,P=0.002)在完全血运重建组也显著降低,其余次要终点无显著差异。结论认为FFR指导的完全血运重建在索引操作中显著降低1年复合终点,主要由再次血运重建减少驱动。

要点

  • NSTEMI合并多支血管病变且罪犯血管成功血运重建后,FFR指导完全血运重建较仅罪犯血管血运重建降低1年主要复合终点(5.5% vs 13.6%,HR 0.38,95%CI 0.20-0.72,P=0.003)。
  • 完全血运重建组任何血运重建率显著低于仅罪犯血管组(3.0% vs 11.5%,HR 0.24,95%CI 0.11-0.56,P<0.001)。
  • 完全血运重建组净不良临床事件显著低于仅罪犯血管组(6.3% vs 15.3%,HR 0.39,95%CI 0.21-0.70,P=0.002)。
  • 主要终点获益主要由再次血运重建减少驱动,其余次要终点(包括全因死亡、非致死性心肌梗死、卒中、出血事件等)无显著差异。
  • 仅罪犯血管血运重建组允许索引操作后6周内分期血运重建,交叉发生7例。

适用人群与场景

  • NSTEMI合并多支血管病变、且罪犯血管已成功血运重建的患者。
  • 纳入标准包括至少1处非罪犯病变狭窄程度至少50%且适合血运重建。
  • 研究在欧洲9家医院进行,患者于2018年6月至2024年7月入组。

诊断标准与关键阈值

  • 非罪犯病变至少1处狭窄程度至少50%且适合血运重建。
  • 罪犯血管已成功血运重建。

处置流程与药物剂量

  • 随机接受FFR指导的完全血运重建或仅罪犯血管血运重建,均在索引操作中进行。
  • 仅罪犯血管血运重建组允许索引操作后6周内分期血运重建。

研究设计与关键结果

  • 前瞻性、研究者发起、多中心、国际随机临床试验,在欧洲9家医院纳入478例NSTEMI合并多支血管病变患者,平均(SD)年龄65.9(10.6)岁,男性347例(72.9%);FFR指导完全血运重建组240例,仅罪犯血管血运重建组238例,仅罪犯血管组交叉7例。
  • 主要终点(1年全因死亡、非致死性心肌梗死、任何血运重建和卒中的复合终点)在FFR指导完全血运重建组13例(5.5%)vs 仅罪犯血管组32例(13.6%)(HR 0.38,95%CI 0.20-0.72,P=0.003)。
  • 任何血运重建率完全血运重建组3.0% vs 仅罪犯血管组11.5%(HR 0.24,95%CI 0.11-0.56,P<0.001)。
  • 净不良临床事件完全血运重建组6.3% vs 仅罪犯血管组15.3%(HR 0.39,95%CI 0.21-0.70,P=0.002)。
  • 其余次要终点无显著差异。

证据类型、等级与局限

  • 证据类型:前瞻性、研究者发起、多中心、国际随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于NSTEMI合并多支血管病变且罪犯血管已成功血运重建的患者,索引操作中行FFR指导的完全血运重建较仅罪犯血管血运重建可降低1年主要复合终点,主要由再次血运重建减少驱动。
  • 仅罪犯血管血运重建组允许索引操作后6周内分期血运重建,交叉发生7例。
  • 其余次要终点无显著差异。

指南或共识出处

  • SLIM随机临床试验(ClinicalTrials.gov Identifier: NCT03562572)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The benefits of fractional flow reserve (FFR)-guided complete coronary revascularization in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease remain unclear.

OBJECTIVE: To compare FFR-guided complete revascularization of nonculprit lesions vs culprit-only revascularization in patients with NSTEMI and multivessel disease.

DESIGN, SETTING, AND PARTICIPANTS: This prospective, investigator-initiated, multicenter, international randomized clinical trial was conducted at 9 hospitals in Europe. Patients with NSTEMI and multivessel disease who had successful revascularization of the culprit lesion were enrolled between June 2018 and July 2024, and final follow-up was completed on July 21, 2025. The analysis was conducted on July 28, 2025. Eligibility criteria included the presence of at least 1 stenosis of at least 50% in a nonculprit lesion amendable for revascularization.

INTERVENTION: Patients were randomized to receive either FFR-guided complete or culprit-only revascularization during the index procedure. Staged revascularization within 6 weeks after the index procedure was allowed in the culprit-only group.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. Key secondary outcomes included individual components of the primary outcome, net adverse clinical events, all-cause death or nonfatal myocardial infarction, cardiac rehospitalization, and bleeding events.

RESULTS: Among 478 randomized patients (mean [SD] age, 65.9 [10.6] years; 347 [72.9%] males), 240 were randomized to receive FFR-guided complete revascularization and 238 were randomized to receive culprit-only revascularization, with crossover occurring in 7 patients in the culprit-only group. The primary outcome occurred in 13 patients (5.5%) in the FFR-guided complete revascularization group vs 32 patients (13.6%) in the culprit-only group (hazard ratio [HR], 0.38 [95% CI, 0.20-0.72]; P = .003). Rates of any revascularization (3.0% vs 11.5%; HR, 0.24 [95% CI, 0.11-0.56]; P < .001) and net adverse clinical events (6.3% vs 15.3%; HR, 0.39 [95% CI, 0.21-0.70]; P = .002) were also significantly lower in the complete revascularization group, while there were no significant differences in the remaining secondary outcomes.

CONCLUSION AND RELEVANCE: FFR-guided complete revascularization during the index procedure resulted in a significant reduction in the composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. This was mainly driven by reduced repeat revascularization.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03562572.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Pustjens TFS, Veenstra L, Camaro C, et al. Fractional Flow Reserve-Guided Complete vs Culprit-Only Revascularization in Non-ST-Elevation Myocardial Infarction and Multivessel Disease: The SLIM Randomized Clinical Trial. JAMA. 2025. PMID: 40886310. doi:10.1001/jama.2025.16189

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。